| Literature DB >> 30975174 |
Xia Yuan1, Xiangxian Zhang1, Lu Sun1, Yuquan Wei1, Xiawei Wei2.
Abstract
BACKGROUND: Carbon nanomaterials are a growing family of materials featuring unique physicochemical properties, and their widespread application is accompanied by increasing human exposure. MAIN BODY: Considerable efforts have been made to characterize the potential toxicity of carbon nanomaterials in vitro and in vivo. Many studies have reported various toxicology profiles of carbon nanomaterials. The different results of the cytotoxicity of the carbon-based materials might be related to the differences in the physicochemical properties or structures of carbon nanomaterials, types of target cells and methods of particle dispersion, etc. The reported cytotoxicity effects mainly included reactive oxygen species generation, DNA damage, lysosomal damage, mitochondrial dysfunction and eventual cell death via apoptosis or necrosis. Despite the cellular toxicity, the immunological effects of the carbon-based nanomaterials, such as the pulmonary macrophage activation and inflammation induced by carbon nanomaterials, have been thoroughly studied. The roles of carbon nanomaterials in activating different immune cells or inducing immunosuppression have also been addressed.Entities:
Keywords: Carbon nanomaterial; Cytotoxicity; Immunological effects; Macrophage
Mesh:
Substances:
Year: 2019 PMID: 30975174 PMCID: PMC6460856 DOI: 10.1186/s12989-019-0299-z
Source DB: PubMed Journal: Part Fibre Toxicol ISSN: 1743-8977 Impact factor: 9.400
Fig. 1Various carbon-based nanomaterials were reported to induce cytotoxicity. Carbon nanotubes (CNTs) are thin carbon filaments with cylindrical structure that comprise single or multiple graphene sheets, termed as single-wall carbon nanotubes (SWCNTs) and multiwall carbon nanotubes (MWCNTs), respectively. C-fullerene is a carbon allotrope organized solely by 60 carbon atoms with a polygonal structure. Carbon black nanoparticle is a traditional nanosized carbon-based nanomaterial of diameter between 10 to 100 nm with three nanometric dimensions. Nanographite, also called graphite nanoplatelet, is a one-atom-thick and two-dimensional sheet of sp2-bonded carbon atoms. Single-walled carbon nanohorns (SWCNHs) are horn-shaped single-walled tubules with cone angles of approximately 20°
Examples of in vitro studies on cellular toxicity of various carbon-based nanomaterials
| Types | Length | Diameter | Dose | Target cells | Cytotoxicity | Reference |
|---|---|---|---|---|---|---|
| Carbon nanotubes; | 1.5 μm; | 9.5 nm; | 15~120 μg/ml | RAW 264.7 | LDH release, TNF-α production, ROS production | [ |
| Pristine graphene | 500-1000 nm | 2~3 nm | 5, 10, 20, 40, 80 and 100 μg/ ml | RAW 264.7 | ROS increase, apoptosis by activation of the mitochondrial pathway, activation of the MAPKs (JNK, ERK and p38) and the TGF-beta-related signaling pathways | [ |
| SWCNTs | — | — | 0.78~200 μg/ml | HEK293 cell | Apoptosis and cell cycle arrest in G1. | [ |
| Water-soluble fullerene | — | — | — | Human dermal broblasts, HepG2, neuronal human astrocytes | Lactate dehydrogenase release, cellular membrane disruption and lipid peroxidation | [ |
| SWCNTs; | — | 1-2 nm; | 5~100 μg/ml | NR8383 cell | ROS generation and reduced cell viability. | [ |
| Graphene oxides (GOs); | — | 500 nm; | 10~50 μg/ml | Peritoneal macrophages | LDH release, decreased autophagic degradation, lysosomal membrane destabilization | [ |
| SWCNTs | 150 nm | 1~2 nm | 0~50 μg/ml | Mouse peritoneal macrophages | Mitochondrial damage | [ |
| MWCNT1; | 13 μm; | 40~100 nm; | 0.625~10 μg/cm2 | RAW 264.7 | Mitochondrial activity reduction, LDH release | [ |
| Aci- and tau-MWCNTs | 5~10 μm | 10~20 nm | 0, 5, 20, 40, and 80 μg/ml | RAW 264.7 | Apoptosis via mitochondrial pathway and scavenger receptor | [ |
| SWCNT; | 1~5 μm; | < 2 nm; | 30, 100 and 300 μg/ml | RAW 264.7 | Cell death induced by SWCNT; | [ |
| SWNTs; | 1 μm; | 1.4 nm; | 1.41~226.0 μg/cm2; | Alveolar macrophage | Reduced cell viability | [ |
| C-SWNTs; | — | — | — | Human monocytes-derived macrophages | apoptosis/necrosis | [ |
| Carbon black nanoparticles | 175± 80 nm | 20± 6 nm | 30 μg/cm2 | RAW264.7, human alveolar macrophages | Caspase 1 and IL-1β release, LDH release, plasma membrane disruption, pyroptosis | [ |
| Fe@CNPs | — | — | 50 and 400 μg/ ml | HEK293 and C33A cell | ROS generation and apoptosis | [ |
| SWCNHs | 400 nm | ~100 nm | 0.01~0.3 mg/ml | RAW 264.7 | Apoptosis and necrosis associated with lysosomal membrane destabilization, ROS generation, inflammatory cytokines (TNF-α, IL-1β, and IL-6) release | [ |
| MWCNTs | 0.5-2 μm | < 8 nm; | 100 μg/ml | 3T3, RAW 264.7 and bronchiolar epithelial cells. | Cytotoxicity differing with particle sizes and cell types, reactive oxygen species generation, lysosomal membrane destabilization and mitochondrial permeability. | [ |
| SWCNTs | — | 0.8~2.0 nm | 25 or 50 μg/cm2 | Normal and malignant human mesothelial cells | ROS generation, increased cell death, enhanced DNA damage and H2AX phosphorylation, and activated PARP, AP-1, NF-κB, p38, and Akt | [ |
| MWCNTs | < 1μm | 9.5 nm | 2.5~100 μg/ml | RAW264.7, A549 | LDH release and oxidative stress | [ |
| Carbon nanohorns | — | — | 1~100 μg/ml | RAW 264.7 | Reactive oxygen species generation and apoptosis lysosomal membrane permeabilization | [ |
| Pristine-SWCNTs | — | — | 1 μg/cm2 | RAW264.7 | Decreased cell viability and ATP production, increased ROS and NO production, activation of the MAP kinase pathway, increased levels of apoptosis- and autophagy-related proteins and ER stress-related proteins | [ |
| Functionalized MWCNTs (tau-MWCNTs); | 300~600 nm; | 10~20 nm; | 0~ 80 μg/ml | RAW 264.7 | Apoptosis related to mitochondrial injury, less toxicity induced by tau-MWCNTs | [ |
| MWCNTs | — | — | 20 μg/ml | Mature human monocyte-derived macrophage cells | Apoptosis and necrosis | [ |
| Short MWCNTs; | 0.6 μm; | 30.6 nm; | 10 μg/ml | Primary human alveolar macrophage | Reduced cell viability, ROS generation and inflammatory mediator release induced by long MWCNTs. | [ |
| MWCNTs; | ~2 μm; | 10~15 nm; | 0~500 μg/ml | 16HBE14o- | ROS generation, reduced cell viability | [ |
| MWCNTs-COOH; MWCNTs-PEG | 0.9 μm; | 24.6 nm; | 0~100 μg/ml | RAW 264.7 cells, primary rat peritoneal macrophages | Activation of oxidative stress-responsive pathways, such as p38 mitogen-activated protein kinases (MAPK) and nuclear factor (NF)-κB | [ |
| Purified-MWCNT; COOH-MWCNT | 1122 nm; | — | 1~50 μg/ml | Human alveolar macrophage | Reduced cell viability and increased inflammatory mediator (IL-1β and IL-8) release | [ |
| Two types of functionalized carbon nanotubes (1,3-dipolar cycloaddition reaction and the oxidation- /amidation treatment) | — | — | 1~10 μg/ml | Primary B lymphocytes, T lymphocytes, and peritoneal macrophages | Intake by B and T lymphocytes as well as macrophages in vitro without affecting cell viability. | [ |
Fig. 2The mechanisms by which carbon-based nanoparticles induce cytotoxicity of macrophages. Exposure of macrophages to carbon nanomaterials triggers a cascade of cellular and molecular events, such as ROS generation and lysosome damage, which serve as the mechanisms underlying carbon nanomaterial-induced cell death, including necrosis, apoptosis and pyroptosis. Carbon nanomaterials cause the mitochondrial dependent apoptotic cascades through ROS-activated MAPKs pathway. ROS could activate several transcription factors, such as NF-κB that regulates the inflammatory response. Carbon nanomaterials induce lysosomal membrane permeabilization (LMP), resulting in the translocation of cathepsins to the cytoplasm. ROS and LMP were reciprocal causation generating an amplification loop. LMP could potentially cause autophagy dysfunction. And inflammasome-dependent pyroptosis was initiated characterized by cleavage of caspase 1 and downstream IL-1β release
In vivo studies on immunological properties of carbon-based nanomaterials
| Test materials | Exposure pathways | Exposure doses | Suspension buffer | Time points of sacrifice | Test animals | Main findings | Refe-rence |
|---|---|---|---|---|---|---|---|
| MWCNTs | Pharyngeal aspiration | 40 μg/mouse | PBS with 0.6 mg/mL serum albumin and 0.01 mg/mL 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DSPC) | 24 h, 7 days, and 28 days | C57BL/6 mice aged 10 weeks | An early increase in serum cytokines and inflammatory gene expression in serum; consistently increased eosinophils in blood and BALF. | [ |
| Biodegraded and non-biodegraded carbon nanotubes | Pharyngeal aspiration | 40 μg/mouse | PBS for non-biodegraded CNTs; PBS with hMPO and H2O2 for biodegrated CNTs | 7 days | C57BL/6 mice | No pro-inflammatory pulmonary response observed in mice treated with biodegraded nanotubes. | [ |
| Carbon black nanoparticles | Intratracheal instillation (single) | 0.018, 0.054 or 0.162 mg/mouse | 0.9% NaCl | 1, 3 and 28 days | Female C57BL/6 mice aged 5-6 weeks | Strongest lung inflammation on day 1 and day 3 post exposure, elevating for the two highest doses (0.054 and 0.162 mg) 28 days post-exposure. | [ |
| High-purity WMCNTs | Orotracheal aspiration | 4 mg/kg body weight | PBS with 1% Pluronic F127 | 1 h, 6 h, 12 h, 18 h, 24 h, 48 h and 72 h | CF-1 Non-Swiss Albino mice aged 6 weeks | Time-dependent neutrophil influx and pro-inflammatory mediator (TNF-α and IL-6) release in bronchoalveolar lavage (BAL) fluid; attenuated influx of neutrophils in AM-depleted mice. | [ |
| MWCNTs | Intratracheal instillation; inhalation | 0.2 mg or 1 mg/mouse; 0.37mg/m3 aerosols (6 h/day, 5 days/week) for 4 weeks | Distilled water with 0.05% Triton X | 3 days, 1 week, 1 month, 3 months, and 6 months; | Male Wistar rats aged 9 weeks | Less amounts of MWCNTs delivered into the lungs, and therefore less pulmonary inflammation responses in the group of inhalation exposure compared to intratracheal instillation. | [ |
| SWCNTs | Intratracheal instillation | 0.04, 0.2, 1 mg/kg body weight | PBS with 10 mg/mL Tween 80 | 3 days, 1 week, 1 month, 3 months and 6 months | Male Crl: CD (SD) rats aged seven weeks | Increased inflammatory cells in BALF in a dose-dependent manner from 3 days post-exposure up to 3 months; alveolar macrophage accumulation and inflammatory cell infiltration in the lung sections. | [ |
| Long tangled MWCNTs and long rod-like MWCNTs | Pharyngeal aspiration | 10 or 40 μg/mouse | PBS with 0.6 mg/ml BSA | 4 and 16 h or 7, 14, and 28 days | Female C57BL/6 mice aged 7–8 weeks | Attenuated inflammatory reactions caused by CNTs in IL-1R-/-mice and antagonist-treated (etanercept and anakinra) mice | [ |
| MWCNTs | Pharyngeal aspiration | 5, 20, or | Ca2+ and Mg2+-free PBS with 0.6 mg/ml mouse serum albumin and 0.01 mg/ml DPPC | 1, 3, 7 and 14 days | Male C57BL/6J mice aged 8 weeks | Rapid and prominent fibrosis formation remarkably near where the particles were deposited in the lungs; pronounced infiltration of neutrophils and macrophages alongside fibrosis. | [ |
| SWCNTs and fullerenes | Intratracheal instillation | Low dose: 0.0003, 0.0015, 0.003, 0.015, and 0.3 mg/mouse; high dose: 0.1 and 0.5 mg/mouse | Pluronic F-68 | 7 days | Male ICR mice aged 5-6 weeks | Airway hyperreactivity and airflow obstruction; upregulation of cathepsin K, MMP-12, CCL2 and CCL3, and macrophage receptors such as Toll-like receptor 2 and macrophage scavenger receptor 1. | [ |
| SWCNTs, MWCNTs and ultrafine carbon black particles | Subcutaneous injection into the footpad together with OVA; | For the injection model, ~200 μg /single dose (max dose with fourfold dilutions) for 3 doses; for the intranasal model, 133 μg/day for 3consecutive days | Hank’s balanced salt | An OVA booster on days 21, sacrificed on days 26; An OVA booster on days 21,22 and 23, sacrificed on days 26. | Female inbred BALB/cAnNCrl mice aged 6–7 weeks | Increased serum levels of OVA-specific IgE, number of eosinophils in BALF, and secretion of Th2-associated cytokines in the mediastinal lymph node in the group of CNTs together with OVA; increased IgG2a levels, neutrophil cell numbers, and levels of TNF-α and MCP-1 in BALF in the group of MWCNT and ufCB with OVA. | [ |
| MWCNTs | Intratracheal instillation | 50 μg/mouse once a week for 6 weeks | PBS with 0.05% Tween 80 | 24 h after the final intratracheal administration | Male ICR mice aged 6-7 weeks | Aggravated airway inflammation observed in the group of OVA+MWCNTs, characterized by infiltration of immune cells and production of cytokines; increased levels of serum immunoglobulin (allergen-specific IgG1 and IgE) compared with OVA alone. | [ |
| Carbon nanoparticles | Pharyngeal | 2.5 mg/kg body weight | PBS | 12 h, 24 h, 48 h | Female Balb/cJRj mice aged 8 weeks | Increased allergic airway inflammation and specific Th2 response in the lymph nodes to OVA in the presence of carbon nanoparticles. | [ |
| Carbon nanoparticles | Intratracheal instillation | 20 μg/mouse | Pyrogene-free | 3, 6, 12, 18, 24 h, and 3 or 7 days | Female C57BL/6 J mice aged 8–10 weeks | Prominent culmination of neutrophil granulocytes 12 to 24 h after instillation; BAL concentrations and increased levels of neutrophil chemoattractants (CXCL1, -2 and-5) from alveolar epithelial type II cells. | [ |
| MWCNTs | Intranasal instillation | administered on days 0, 7, and 14 (75 μg/dose) | A synthetic lung surfactant | On the day 23 | Male BALB/cByJ mice aged 9 weeks | Aggravated airway inflammation and the generation of epithelium-derived innate cytokines caused by the coexposure of MWCNTs and HDM compared to HDM alone. | [ |
| Rod-like MWCNTs and tangled MWCNTs | Inhalation | 6.2-8.2 mg/m3 for rCNT and 17.5-18.5 mg/m3 for tCNT (4 hours at a time once or on four consecutive days) | — | 4 h, 24 h | Female C57BL/6 and BALB/c mice aged 7–8 weeks | Allergic-like airway inflammation and the upregulation of innate immunity-relevant genes and cytokine/chemokine pathways caused by rod-like CNTs after 4-hour exposure. | [ |
| MWCNTs | Oropharyngeal aspiration | 4 mg/kg body weight | Saline with 10% surfactant | 1 or 30 days | C57BL/6J and B6.Cg-kit (W-sh) mast cell deficient mice aged 4–10 weeks | Involvement of mast cells and the | [ |
| MWCNTs | Intratracheal instillation | 5, 20, and 50 mg/kg body weight | PBS | 1,3, 7,14 days | Male ICR mice | Increased pro-inflammatory cytokines in BALF and in blood in a dose-dependent manner, peaking at day 1 postexposure; more pronounced elevation of Th2-type cytokines than that of Th1-type cytokines; considerably enhanced number of B cells in the spleen and blood. | [ |
| MWCNTs | Intravenous injection | 100 μg/mouse | Ca2+ and Mg2+-free PBS | 24 h, 7 days and 15 days | Female C57BL/6 mice aged 6-8 weeks | Proliferative response of T lymphocytes to a nonspecific mitogen and to ovalbumin (OVA); an increase in expression of proinflammatory cytokines such as TNF-α and IL-6 and IFN-γ, and a decrease in TGF-β and IL-10; increased antibody production to OVA in the treated group. | [ |
| nonPEGylated SWCNTs | Intravenous injection | 1.2 mg/kg body weight | PBS | 6 min and | Male Wistar rats of body weight 250–280 g | A significant rise in plasma thromboxane B2 levels. | [ |
| MWCNTs | Inhalation | 0.3, 1, or 5 mg/m3 (6 h/day) for 7 or 14 days | — | 7 or 14 days | Male C57BL/6 mice aged 10 weeks | An absence of severe inflammation and tissue injury; decreased NK cell function and T cell-dependent antibody response. | [ |
| MWCNTs | Inhalation | 0, 0.3 or 1 mg/m3 (6 h/day) for 14 consecutive days | — | — | Male C57Bl/6 mice aged approximately 8 weeks | A dose-dependent decrease in antibody formation in response to antigen, not altering lymphocyte subpopulations; activation of the cyclooxygenase pathway in the spleen by MWCNTs through TGF-ß release in the lung, leading to T-cell dysfunction and decreased T-cell-dependent antibody formation. | [ |
| MWCNTs | Pharyngeal aspiration | 50 μg/mouse | PBS with 0.6 mg/ml mouse serum albumin and 0.01 mg/ml DPPC | day 7, 28 | Wild-type C57BL/6 and IL-1R-/- mice aged 2 months | Severe acute pulmonary inflammation, and increases of TNF-α, IL-6, IL-1β and MCP-1 protein levels in BALF in wild-type mice; reduced pulmonary inflammatory response in IL-1R-/- mice exposed to MWCNT. | [ |
| Four samples of MWCNTs: NTtang1 (diameter ~14.84 nm, length 1-5 μm), NTtang2 (diameter ~10.40 nm, length 5-20 μm), NTlong1 (diameter ~84.89 nm, mean length 13 μm) and NTlong2 (diameter ~165.02 nm, max length 56 μm) | Intraperitoneal injection | 50 μg/mouse | Saline with 0.5% BSA | 24 h and 7 days | Female C57BL/6 mice aged 8 weeks | Significant polymorphonuclear leukocyte (PMN) or protein exudation and granulomas formation on the peritoneal side of the diaphragm in the group of long-fiber-containing samples. | [ |
| Nano-sized carbon black | Inhalation | For a 3-day experiment, 13.08 ± 3.18 mg/m3 of non-sonicated carbon black (group N) and 13.67 ± 3.54 mg/m3 of sonicated carbon black (group S); for a 2-week experiment, 9.83 ±3.42 mg/m3 of non-sonicated carbon black and 9.08 ± 4.49 mg/m3 of sonicated carbon black. (exposed 6 h/day, 5 days/week for 3 days or 2 weeks) | Distilled water | — | Male Sprague-Dawley (SD) rats aged 5 weeks | More carbon black particles-laden macrophages observed in BALF and more carbon black deposited in the lungs exposed to sonicated carbon black; no significant difference in the levels of inflammatory cytokines or damage-indicating proteins between the two groups in the 3-day experiment, whereas 2-week exposure induced increased number of total cells, macrophages, and PMNs in the group S. | [ |
| SWCNTs, MWCNTs (diameter 10-15 nm), MWCNTs (diameter 20-50 nm) and MWCNTs (diameter 3-10 nm) | Intratracheal instillation | 100 mg/rat | NaCl solution with or without 0.5 mg/ml BSA | 24 h | Male Sprague Dawley rats of body weight 180-220 g | Remarkably accentuated inflammatory cell infiltration in BALF, and increased the number of CNT-loaded alveolar macrophages, caused by CNTs dispersed in BSA, but not in NaCl solution, indicating the potential importance of CNT dispersion for the toxicological studies. | [ |
| Several types of covalently functionalized MWCNTs: COOH-MWCNTs, sw-NH2- MWCNTs, NH2-MWCNTs, PEG-MWCNTs and PEI-MWCNTs | Oropharyngeal aspiration | 2 mg/kg body weight | PBS with or without 0.6 mg/mL BSA | 40 h or 21 days | Male C57BL/6 mice aged 8 weeks | Obvious lung fibrosis induced by cationic PEI-MWCNTs, whereas reduced pulmonary fibrosis observed in the group of MWCNT-COOH. | [ |
| Tau-MWCNTs and raw MWCNTs | Intratracheal instillation | 0.125, 0.25, 0.5 or 1 mg/kg body weight | PBS | 1, 7, 14 or 28 days | Male CD-1 (ICR) mice of body weight 18∼22 g | Less toxic induced by Tau-MWNTs than insoluble raw MWNTs | [ |
Fig. 3MyD88 played a critical role in alveolar macrophage-mediated inflammatory response to CNTs. MyD88 mediated CNTs toxicity by linking IL-1R or TLR-dependent signaling and acted on downstream IRAKs and TRAFs, thus inducing proinflammatory NF-κB pathway. Also, MAPKs was involved in toxic response and MAPK inhibitors for p38 and JNK reduced levels of TNF-α and IL-1β. MyD88-specific inhibitory peptide blocked the production of TNF-α and IL-1β
Fig. 4SWCNTs induced lung injury. Inhalation of SWCNTs could up-regulate chemokines, proteinases and several macrophage receptors, also resulting in NF-κB-related inflammatory responses, which play roles in lung pathology including airway hyperreaction, airflow obstruction and granuloma. In vitro experiments indicated that the cell-cell interaction of bronchoalveolar macrophages with lung epithelial cells induced MMP12 and cathepsin K. Blocking NF-κB with PDTC could attenuate SWCNTs-induced chemokine and proteinase expression